SCHEMBL3343002

SCHEMBL3343002

OC[C@@H](O)CF

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1217198 1.00
SCHEMBL3343095 1.00
Ammonia Solution, Strong SCHEMBL4617478 0.96
1,3-Butanediol SCHEMBL11167714 0.81 THRB (0.50)
SCHEMBL25557 0.79
Hydrochloric Acid SCHEMBL19925359 0.75
Glycerin SCHEMBL10453101 0.74 LMNA (1.00)
Glycerin SCHEMBL3418854 0.74 LMNA (1.00)
Glycerin SCHEMBL8080917 0.74 LMNA (1.00)
Glycerin SCHEMBL14278797 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368627-A1 PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS Peloton Therapeutics, Inc., a fully owned subsidiary of Merck Sharp & Dohme LLC (US) 2025-12-04 US disclosed
CN-111909173-B Benzoxazepine oxazolidinone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2025-03-04 CN disclosed
EP-3953331-B1 PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS PELOTON THERAPEUTICS INC (US) 2024-11-20 EP disclosed
CN-112047960-B Benzoxazepine oxazolidinone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2024-08-02 CN disclosed
CN-112062778-B Benzoxazepine oxazolidinone compounds and methods of use thereof 豪夫迈·罗氏有限公司 2024-04-19 CN disclosed
US-11553713-B2 Polyalcohol, carbohydrate, nucleobase and nucleotide compositions and uses thereof Zhang, Chunbo (US) 2023-01-17 US disclosed
US-20220162193-A1 PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS PELOTON THERAPEUTICS, INC. (US) 2022-05-26 US disclosed
CN-108697077-B Polyol, carbohydrate, nucleobase and nucleoside compositions and uses thereof 组合块公司 2022-04-19 CN disclosed
EP-3953331-A1 PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS Peloton Therapeutics, Inc. (US) 2022-02-16 EP disclosed
WO-2020210139-A1 PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS PELOTON THERAPEUTICS, INC. (US) 2020-10-15 WO disclosed
US-20200236932-A1 POLYALCOHOL, CARBOHYDRATE, NUCLEOBASE AND NUCLEOTIDE COMPOSITIONS AND USES THEREOF ZHANG, CHUNBO 2020-07-30 US disclosed
WO-2017053467-A1 POLYALCOHOL, CARBOHYDRATE, NUCLEOBASE AND NUCLEOSIDE COMPOSITIONS AND USES THEREOF COMBI-BLOCKS, INC. (US) 2017-03-30 WO disclosed
WO-2012150220-A1 RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-11-08 WO disclosed
EP-2364973-A1 Heterocyclic inhibitors of MEK and Methods of use thereof Array Biopharma, Inc. (US) 2011-09-14 EP disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
EP-1967516-B1 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA INC (US) 2009-11-04 EP disclosed
WO-2007044084-A2 HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2007-04-19 WO disclosed
US-5846793-A Microbial process for biotransformation to (R)-3-chloro-1,2-propanediol KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-12-08 US disclosed
EP-0286059-B1 PROCESS FOR PREPARING (R)-3-CHLORO-1, 2-PROPANEDIOL KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1992-07-01 EP disclosed
EP-0286059-A1 Process for preparing (R)-3-Chloro-1, 2-Propanediol KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-10-12 EP disclosed